Clinical Trial Update: Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression [Phase 1]

View source ↗

Summary

A Phase 1 trial from GlaxoSmithKline evaluated Danirixin (GSK1325756) for its ability to inhibit CD11b cell surface expression in the setting of respiratory syn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Danirixin (GSK1325756) (Danirixin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Respiratory Syncytial Virus | Phase 1 | Status: COMPLETED